Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Angiomax · 2 trials · 3 indications
In-hospital acute procedural success, defined as the absence of death, Q wave MI, repeat coronary revascularization, and stroke (hemorrhagic or ischemic) at hospital discharge or Day 7 after surgery ('Day 7/discharge'), whichever occurs first.
| Name | Type | Description |
|---|---|---|
| Angiomax (bivalirudin) | DRUG | 250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. A starting bolus of 0.1 mg/kg and/or an infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended. |
Inclusion Criteria * Provide written informed consent before initiation of any study-related procedures, and * Be at least 18 years of age, and * Be scheduled for CABG, CABG single valve surgery, or isolated single valve surgery on CPB. Patients undergoing repeat (redo) CABG are also considered eli...
Angiomax is a small molecule cardiovascular drug being developed by Novartis AG for cardiovascular disease and thrombosis. It has been studied in patients with heparin-induced thrombocytopenia or heparin-induced thrombocytopenia with thrombosis syndrome type II undergoing coronary artery bypass surgery, as well as in infants under six months with thrombosis.
Angiomax is being developed by Novartis AG, which is publicly traded under the ticker NVS. The drug is a small molecule therapeutic in the cardiovascular area.
Angiomax has completed Phase 3 clinical trials. It is an investigational drug and remains in clinical development, with no approval status indicated in the available trial data.
Angiomax has been studied in two completed clinical trials. NCT00079508 was a Phase 3 study in patients with HIT or HITTS type II undergoing coronary artery bypass surgery, enrolling 125 participants. NCT00043277 was a Phase 2 study in infants under six months with thrombosis, enrolling 25 participants.
Angiomax is a small molecule drug, but its specific molecular target is not disclosed in the available information. It is being studied for its effects in cardiovascular disease and thrombosis, particularly in the context of heparin-induced thrombocytopenia.
Angiomax is the brand name for bivalirudin, a direct thrombin inhibitor. The drug is being developed by Novartis AG for use in cardiovascular procedures and thrombotic conditions.